Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Cochlear (ASX:COH) share price in focus with profit down in HY21

The Cochlear Limited (ASX:COH) share price will be in focus after the hearing device business said its underlying profit fell. It's expecting growth in FY21 H2.

The Cochlear Limited (ASX: COH) share price will be in focus today after the hearing device business revealed that its HY21 underlying profit declined, but it’s expecting growth in the second half.

What happened in Cochlear’s result?

Cochlear announced that its sales revenue declined by 4% to $742.8 million, with the first quarter down 8% and the second quarter up 7% (in constant currency terms). This was with cochlear implant units being down 8% to 17,377.

The healthcare business said it experienced improving momentum across the half as surgeries recovered following COVID shutdowns.

There was strong growth in the US, Japan, South Korea and China, with improving momentum in Europe. However, there has been a slower recovery across most emerging markets.

Underlying EBIT (EBIT explained) dropped by 4% to $175.6 million. Underlying net profit after tax (NPAT) fell by 6% to $125.3 million. Cochlear said that this was driven by a solid recovery in sales revenue and lower operating expenses due to material COVID-related savings.

However, the statutory net profit saw a large increase of 50% to $236.2 million. This includes three different elements: $59 million for patent litigation-related tax and other benefits, $17.2 million of COVID-19 government assistance and $34.7 million of innovation fund gains (including the revaluation of investments and equity accounted losses).

The innovation fund has made several small investments in companies with technologies that may help Cochlear over the longer term. The $34.7 million in non-cash gains related to Nyxoah and EpiMinder. Nyxoah listed in September.

Cochlear dividend

Cochlear’s board has decided to re-introduce the dividend as a result of improving trading conditions and cashflow generation.

It will pay out 60% of its underlying net profit, equating to an interim dividend of $1.15 per share – down 28%.

It’s going to return jobkeeper

Cochlear has decided to repay $24.6 million of government assistance as trading conditions improved. It said it was the appropriate thing to do.

FY21 outlook

Cochlear said that it’s expecting to deliver underlying net profit of $225 million to $245 million, which would be a 46% to 59% increase compared to FY20.

It’s expecting further improvements over the rest of the financial year, however the strength of the Australian dollar is expected to have a material impact on second half profit with over 95% revenue derived from overseas while only 50% of expenses are in foreign currencies.

Considering the high level of COVID-19 disruption, this was a solid result and it’s promising that it’s expecting big profit growth for the whole year.

Before you consider Cochlear, I suggest getting a free Rask account and accessing our full stock reports. Click this link to join for free and access our analyst reports.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content